Clinical Trials Logo

Filter by:
NCT ID: NCT01084005 Completed - Clinical trials for Diabetes Mellitus, Type 2

Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes

Start date: March 2010
Phase: Phase 3
Study type: Interventional

The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to placebo given for 24 weeks as add-on therapy to stable treatment in elderly patients with T2DM with insufficient glycaemic control

NCT ID: NCT01082874 Completed - Clinical trials for Cardiovascular Disease

PeriOperative ISchemic Evaluation-2 Trial

POISE-2
Start date: July 2010
Phase: Phase 3
Study type: Interventional

Major surgeries not involving the heart are common, and major heart problems during or after such surgeries represent a large population health problem. Few treatments to prevent heart problems around the time of surgery have been tested. There is encouraging data suggesting that small doses of Acetyl-Salicylic Acid (ASA) and Clonidine, which are two medications, given individually for a short period before and after major surgeries may prevent major heart problems. The POISE-2 Trial is a large international study to test if ASA and Clonidine can prevent heart attacks and deaths from heart problems around the time of surgery.

NCT ID: NCT01081678 Completed - Fracture Healing Clinical Trials

Study To Assess FRacTure Healing With SclerosTin Antibody - Hip

STARTT-Hip
Start date: June 20, 2010
Phase: Phase 2
Study type: Interventional

This is an international, multi-center study to determine the efficacy, safety, and tolerability of romosozumab (AMG 785) in adults with a fresh unilateral hip fracture, status post surgical fixation.

NCT ID: NCT01081522 Completed - Pilonidal Sinus Clinical Trials

A Preliminary, Non-comparative Study to Evaluate a Bioresorbable Wound Scaffold in Acute Wounds

Start date: October 2009
Phase: N/A
Study type: Observational

As this is a proof-of-concept study, the primary objective is to provide preliminary data on the safety and efficacy of Bioresorbable Wound Scaffold in the management of acute wounds left to heal by secondary intent.

NCT ID: NCT01080352 Completed - Prostatic Neoplasms Clinical Trials

Vitamin C as an Anti-cancer Drug

Start date: November 2010
Phase: Phase 2
Study type: Interventional

Can high dose, intravenous Vitamin C prolong life for patients with metastatic prostate cancer? Prostate cancer is the most common cancer (excluding skin cancer) in men in Denmark and the Unites States. When metastatic disease is present cure is no longer possible. The main treatment at this stage is castration, either surgical or medical, ending the patients testosterone production and causing a temporary regression in disease activity. Eventually, the cancer will progress, usually within 2 years from the castration, with a more aggressive course and a survival of 2-3 years. The current treatment option for the patients, who have undergone castration and have disease progression, is chemotherapy with only limited gains in quality of life and survival. This clinical study is a phase 2 study to evaluate the effects of high dose intravenous vitamin c in subjects with early castration resistant prostate cancer. Primary endpoint: - Prostate specific antigen (PSA) changes after 12 to 20 weekly vitamin c infusions Secondary endpoints: - Bone metastases changes after 12 to 20 weekly vitamin c infusions - Changes in bone specific alkaline phosphates, oxidative DNA-damage, PINP, NTX after 12 to 20 weekly vitamin c infusions - RNA-expression changes in prostatic tumor tissue after 12 to 20 weekly vitamin c infusions - RNA-expression changes in lymphocytes after 12 to 20 weekly vitamin c infusions Tertiary endpoints: - Pharmacokinetics of vitamin c in the elderly cancer patients Methods and material: - 80 subjects are included (efficacy evaluation when 20 subjects have been evaluated for extension arm) - Each subject receives a weekly infusion of 60 grams vitamin c (in the form of ascorbate) for 12 to 20 weeks

NCT ID: NCT01078480 Completed - Clinical trials for Displaced Midshaft Fracture of the Collar Bone

Conservative Treatment Compared to Osteosynthesis in Patients With a Fractured Collar Bone

Start date: April 2010
Phase: N/A
Study type: Interventional

This study will compare non-operative treatment of displaced midshaft collarbone fractures with operative treatment using a precontoured titanium plate and screws. The study hypothesis is that operation will provide better pain relief, faster return to activities, better function of the involved upper limb, and lower the risk of a non healing fracture (non union).

NCT ID: NCT01078103 Completed - Diabetes Clinical Trials

Corneal Endothelial Changes Associated With Phacoemulsification in Diabetes Mellitus Type II

Start date: July 2005
Phase: Phase 4
Study type: Observational

Some studies indicated that the diabetic corneal endothelium is morphologically abnormal and may be at risk in any intraocular surgical procedure, while others showed no significant differences between diabetic and non-diabetic corneal endothelium.The purpose of this study is to investigate the differences in corneal endothelial cell density and morphology in diabetic patients and normal patients after phacoemulsification with intraocular lens implantation.To investigate if haemoglobin A1c can be used as a predictor of corneal endothelial cell changes after phacoemulsification.

NCT ID: NCT01077466 Completed - Clinical trials for Secondary Progressive Multiple Sclerosis

Natalizumab Treatment of Progressive Multiple Sclerosis

NAPMS
Start date: March 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to study safety and efficacy of natalizumab treatment of primary and secondary progressive multiple sclerosis. This will be done by measuring the effect of treatment on inflammation in the CNS by means of osteopontin levels in the cerebrospinal fluid (CSF). Safety measures further includes physical and neurological examination,blood samples and MRI measures of disease activity.

NCT ID: NCT01076374 Completed - Arrhythmia Clinical Trials

MEDTRONIC ADAPTA, VERSA AND SENSIA nEw3 POST APPROVAL STUDY

Start date: July 2008
Phase:
Study type: Observational

The primary purpose of this study is to assess the long term reliability of the Medtronic Adapta®/Sensia™/Versa™ platform of devices. This study is required by FDA as a condition of approval of nEw3 devices. Patients will be followed for 5 years after implant. This study utilizes data collected from the System Longevity Study (SLS).

NCT ID: NCT01076361 Completed - Heart Failure Clinical Trials

Model 4968 CAPTURE EPI® STERIOD-ELUTING BIPOLAR EPICARDIAL PACING LEAD Post-approval Study

4968
Start date: September 1999
Phase: N/A
Study type: Observational [Patient Registry]

The Medtronic CapSure Epi Lead Post-approval Study will assess long-term safety of the 4968 lead. This study is part of the Medtronic System Longevity Study.